Delayed global standardization and prefectural disparities in systemic lupus erythematosus treatment in Japan: A nationwide study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.

• Tác giả: Eisuke Inoue, Yuzaburo Inoue, Masakazu Matsushita, Takako Miyamae, Masaaki Mori, Ryoko Sakai, Masaki Shimizu, Ken Yamaji, Naoto Yokogawa
• Ngôn ngữ: eng
• Thông tin xuất bản: England : Modern rheumatology , 2025
• Bộ sưu tập: NCBI
• ID: 215230

Tóm tắt

 OBJECTIVES: The aim of this study was to evaluate the status of the global standardization of, and prefectural differences in, systemic lupus erythematosus (SLE) treatments in Japan. METHODS: The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB Japan) was used. A patient with SLE was defined as having a disease with ICD-10 code M321 or M329 between April 2019 and March 2020, for which oral corticosteroids, immunosuppressive agents, or biologic agents were prescribed at least once during a given month. SLE treatments were evaluated by treatment centre type and prefecture. RESULTS: In total, 74,277 patients met the definition of SLE. The SLE prevalence was 60 per 100,000 (range: 47-102 per 100,000 by prefecture). Nationwide, 79.4% of the patients (range: 52.1-93.3% by prefecture) visited a specialized treatment centre (STC)
  37.4% (range: 26.4-51.3% by prefecture) received only oral corticosteroids, with fewer of these patients visiting an STC than a non-STC (34.8% and 49.7%, P <
  .001)
  and 21.4% (range: 10.7-35.0%) received hydroxychloroquine, with more of these patients visiting an STC than a non-STC (23.0% and 13.5%
  P <
  .001). CONCLUSIONS: The NDB Japan demonstrated the delayed global standardization of, and prefectural disparity in, SLE treatments in Japan.